Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) EPS (Basic) (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported EPS (Basic) over the past 9 years, most recently at -$1.79 for Q4 2023.

  • For Q4 2023, EPS (Basic) rose 31.15% year-over-year to -$1.79; the TTM value through Dec 2023 reached -$10.35, down 1.97%, while the annual FY2024 figure was -$3.68, 64.31% up from the prior year.
  • EPS (Basic) for Q4 2023 was -$1.79 at Corbus Pharmaceuticals Holdings, up from -$2.27 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.03 in Q2 2019 and troughed at -$10.86 in Q4 2021.
  • A 5-year average of -$1.71 and a median of -$0.48 in 2019 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): surged 114.29% in 2019 and later crashed 21620.0% in 2021.
  • Year by year, EPS (Basic) stood at -$0.41 in 2019, then skyrocketed by 87.8% to -$0.05 in 2020, then crashed by 21620.0% to -$10.86 in 2021, then soared by 76.06% to -$2.6 in 2022, then soared by 31.15% to -$1.79 in 2023.
  • Business Quant data shows EPS (Basic) for CRBP at -$1.79 in Q4 2023, -$2.27 in Q3 2023, and -$2.05 in Q2 2023.